Table 1.
Detailed information of included studies.
| Author (Year), Country | Participants | Fucoidan Source/Molecular Weight | Intervention vs. Control | Intervention Period |
Outcome Measurements (also See Table 2) |
|---|---|---|---|---|---|
| Randomized controlled trials | |||||
| Tsai et al. [5] Taiwan |
Metastatic Colorectal Cancer, n = 54 Median age: 57.46 ± 12.15(F) 62.38 ± 11.72(NF) |
Sargassum hemiphyllum, LMF |
4 g of LMF powder vs. cellulose powder | 6 months | Clinical Patient reported |
| Quasi-experimental study | |||||
| Ikeguchi et al. [21] Japan | Advanced or recurrent colorectal cancer, n = 20 Mean age: 71.3 ± 7.5(F) 69.6 ± 8.8(NF) |
Cladosiphon okamuranus, HMF |
150 ml/day liquid (total 4.05 g fucoidan) versus no fucoidan |
6 months | Clinical Patient reported |
| Ikeguchi et al. [22] Japan | Advanced gastric cancer, n = 24 Mean age: 61.2 ± 11(F) 63.3 ± 16.2(NF) |
Cladosiphon okamuranus, HMF |
150 mL/day liquid (total 4.05 g fucoidan) versus no fucoidan |
6 months | |
| Takahashi et al. [13] Japan | Metastatic cancer n = 20 Mean age: 58.9 (Single group study) |
Cladosiphon novae-caledoniae, LMF |
400 mL/day liquid fucoidan (total 4 g fucoidan) | 4 weeks | Clinical Patient reported |
Note: F: With fucoidan; NF: No fucoidan. LMF: lowmolecular weight fucoidan; HMF: high molecular weight fucoidan.